{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:51:49Z","timestamp":1794073909230,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015223","name":"Danish Diabetes and Endocrine Academy","doi-asserted-by":"publisher","award":["PD005-20"],"award-info":[{"award-number":["PD005-20"]}],"id":[{"id":"10.13039\/100015223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["0153-00178B"],"award-info":[{"award-number":["0153-00178B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF18CC0034900"],"award-info":[{"award-number":["NNF18CC0034900"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Metab Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Fibroblast growth factor 21 (FGF21) analogues are in clinical development as treatments for metabolic and alcohol-associated liver disease. The aim of this study was to characterize the first FGF21 knockout (KO) rat line to validate its utility as a translational animal model that recapitulates human disease. We generated an FGF21 KO rat model and exposed 6-month-old WT and KO rats to either chow (<jats:italic>n<\/jats:italic>\u2009=\u20098 per genotype) or the obesogenic GAN (Gubra Amylin NASH) diet (<jats:italic>n<\/jats:italic>\u2009=\u200916 per genotype) for 12 weeks. Lack of endogenous FGF21 increased plasma transaminases, liver weight, and total levels of liver TG in GAN-fed FGF21 KO rats. FGF21 KO had no impact on body weight, glycaemic traits, or MASH histological endpoints, including hepatic steatosis, NAS score, lobular inflammation, ballooning degeneration, fibrosis stage, or the liver transcriptome. Finally, we demonstrate that endogenous FGF21 does not regulate drinking behaviour in rats.<\/jats:p>","DOI":"10.1038\/s44324-025-00062-5","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:23:25Z","timestamp":1748424205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FGF21 deletion mildly exacerbates hepatic dysfunction in GAN diet and alcohol fed rats"],"prefix":"10.1038","volume":"3","author":[{"given":"Peter","family":"Aldiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte Hasle","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Burm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Or\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Gillum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"62_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"62_CR2","doi-asserted-by":"publisher","first-page":"153994","DOI":"10.1016\/j.metabol.2019.153994","volume":"101","author":"B Tucker","year":"2019","unstructured":"Tucker, B. et al. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism 101, 153994 (2019).","journal-title":"Metabolism"},{"key":"62_CR3","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1210\/en.2009-0532","volume":"150","author":"MK Badman","year":"2009","unstructured":"Badman, M. K. et al. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150, 4931\u20134940 (2009).","journal-title":"Endocrinology"},{"key":"62_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mce.2011.05.003","volume":"342","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol. Cell Endocrinol. 342, 41\u201347 (2011).","journal-title":"Mol. Cell Endocrinol."},{"key":"62_CR5","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1194\/jlr.M033415","volume":"54","author":"AL De Sousa-Coelho","year":"2013","unstructured":"De Sousa-Coelho, A. L. et al. FGF21 mediates the lipid metabolism response to amino acid starvation. J. Lipid Res. 54, 1786\u20131797 (2013).","journal-title":"J. Lipid Res."},{"key":"62_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.28523","volume":"64","author":"Q Gong","year":"2016","unstructured":"Gong, Q. et al. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. Hepatology 64, 425\u2013438 (2016).","journal-title":"Hepatology"},{"key":"62_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02677-9","volume":"9","author":"H Li","year":"2018","unstructured":"Li, H. et al. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nat. Commun. 9, 272 (2018).","journal-title":"Nat. Commun."},{"key":"62_CR8","doi-asserted-by":"publisher","first-page":"G378","DOI":"10.1152\/ajpgi.00157.2022","volume":"324","author":"MH Nielsen","year":"2023","unstructured":"Nielsen, M. H. et al. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 324, G378\u2013G388 (2023).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"62_CR9","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1210\/jc.2018-02414","volume":"104","author":"D Barb","year":"2019","unstructured":"Barb, D. et al. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. J. Clin. Endocrinol. Metab. 104, 3327\u20133336 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"62_CR10","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1210\/jc.2013-1250","volume":"98","author":"C Giannini","year":"2013","unstructured":"Giannini, C. et al. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J. Clin. Endocrinol. Metab. 98, 2993\u20133000 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"62_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N. Engl. J. Med. 389, 998\u20131008 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62_CR12","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1210\/clinem\/dgab624","volume":"107","author":"DJ Rader","year":"2022","unstructured":"Rader, D. J. et al. LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. J. Clin. Endocrinol. Metab. 107, e57\u2013e70 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"62_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","volume":"34","author":"KH Flippo","year":"2022","unstructured":"Flippo, K. H., et al. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. Cell Metab 34, 317\u2013328.e6 (2022).","journal-title":"Cell Metab"},{"key":"62_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","volume":"8","author":"MN Kristiansen","year":"2016","unstructured":"Kristiansen, M. N. et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J. Hepatol. 8, 673\u2013684 (2016).","journal-title":"World J. Hepatol."},{"key":"62_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS Tolbol","year":"2018","unstructured":"Tolbol, K. S. et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J. Gastroenterol. 24, 179\u2013194 (2018).","journal-title":"World J. Gastroenterol."},{"key":"62_CR16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/cts.13235","volume":"15","author":"MB Mollerhoj","year":"2022","unstructured":"Mollerhoj, M. B. et al. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. Clin. Transl. Sci. 15, 1167\u20131186 (2022).","journal-title":"Clin. Transl. Sci."},{"key":"62_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"62_CR18","doi-asserted-by":"publisher","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","volume":"46","author":"A Fabregat","year":"2018","unstructured":"Fabregat, A. et al. The Reactome Pathway Knowledgebase. Nucleic Acids Res. 46, D649\u2013D655 (2018).","journal-title":"Nucleic Acids Res."},{"key":"62_CR19","doi-asserted-by":"publisher","first-page":"G449","DOI":"10.1152\/ajpgi.00199.2012","volume":"304","author":"Y Liu","year":"2013","unstructured":"Liu, Y. et al. Animal models of chronic liver diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G449\u2013G468 (2013).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"62_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/biomedicines9040378","volume":"9","author":"L Carreres","year":"2021","unstructured":"Carreres, L. et al. Modeling diet-induced NAFLD and NASH in rats: a comprehensive review. Biomedicines 9, 378 (2021).","journal-title":"Biomedicines"},{"key":"62_CR21","first-page":"1011","volume":"6","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. Am. J. Cancer Res. 6, 1011\u20131025 (2016).","journal-title":"Am. J. Cancer Res."},{"key":"62_CR22","doi-asserted-by":"publisher","first-page":"9923","DOI":"10.7150\/thno.45988","volume":"10","author":"Q Zheng","year":"2020","unstructured":"Zheng, Q. et al. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics 10, 9923\u20139936 (2020).","journal-title":"Theranostics"},{"key":"62_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s12576-018-0595-7","volume":"68","author":"U Yilmaz","year":"2018","unstructured":"Yilmaz, U. et al. Effects of central FGF21 infusion on the hypothalamus-pituitary-thyroid axis and energy metabolism in rats. J. Physiol. Sci. 68, 781\u2013788 (2018).","journal-title":"J. Physiol. Sci."},{"key":"62_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/db09-1878","volume":"59","author":"DA Sarruf","year":"2010","unstructured":"Sarruf, D. A. et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59, 1817\u20131824 (2010).","journal-title":"Diabetes"},{"key":"62_CR25","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","volume":"25","author":"ML Boland","year":"2019","unstructured":"Boland, M. L. et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J. Gastroenterol. 25, 4904\u20134920 (2019).","journal-title":"World J. Gastroenterol."},{"key":"62_CR26","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1073\/pnas.1611243113","volume":"113","author":"G Schumann","year":"2016","unstructured":"Schumann, G. et al. KLB is associated with alcohol drinking, and its gene product beta-Klotho is necessary for FGF21 regulation of alcohol preference. Proc. Natl Acad. Sci. USA 113, 14372\u201314377 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.biopsych.2019.09.011","volume":"87","author":"S Sanchez-Roige","year":"2020","unstructured":"Sanchez-Roige, S., Palmer, A. A. & Clarke, T. K. Recent Efforts to Dissect the Genetic Basis of Alcohol Use and Abuse. Biol. Psychiatry 87, 609\u2013618 (2020).","journal-title":"Biol. Psychiatry"},{"key":"62_CR28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/s41386-022-01526-8","volume":"48","author":"G Augier","year":"2023","unstructured":"Augier, G. et al. Wistar rats choose alcohol over social interaction in a discrete-choice model. Neuropsychopharmacology 48, 1098\u20131107 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"62_CR29","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1046\/j.1440-1746.2003.03198.x","volume":"18","author":"R Kirsch","year":"2003","unstructured":"Kirsch, R. et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18, 1272\u20131282 (2003).","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["npj Metabolic Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44324-025-00062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44324-025-00062-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44324-025-00062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:23:26Z","timestamp":1748424206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44324-025-00062-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1038\/s44324-025-00062-5","relation":{},"ISSN":["2948-2828"],"issn-type":[{"value":"2948-2828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. H. Nielsen, D. Or\u00f3, H. H. Hansen, and M. Feigh are employed by Gubra. M. P. Gillum is employed by Novo Nordisk. None of the other authors has any conflicts of interest, financial or otherwise, to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}